Jefferies Group LLC Reiterates “Buy” Rating for Merus N.V. (MRUS)

Merus N.V. (NASDAQ:MRUS)‘s stock had its “buy” rating reaffirmed by equities research analysts at Jefferies Group LLC in a research report issued to clients and investors on Thursday. They presently have a $30.00 target price on the biotechnology company’s stock. Jefferies Group LLC’s price target would indicate a potential upside of 85.99% from the stock’s previous close.

Several other equities analysts have also issued reports on the company. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $28.00 price target on shares of Merus N.V. in a research report on Wednesday, October 18th. Zacks Investment Research lowered Merus N.V. from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, ValuEngine lowered Merus N.V. from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $30.25.

Shares of Merus N.V. (NASDAQ:MRUS) traded up 1.57% during mid-day trading on Thursday, hitting $16.13. 6,253 shares of the stock traded hands. The company’s 50-day moving average price is $18.55 and its 200 day moving average price is $18.55. Merus N.V. has a 1-year low of $13.13 and a 1-year high of $29.75. The company’s market capitalization is $312.86 million.

COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at

An institutional investor recently bought a new position in Merus N.V. stock. Renaissance Technologies LLC purchased a new position in Merus N.V. (NASDAQ:MRUS) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 22,500 shares of the biotechnology company’s stock, valued at approximately $549,000. Renaissance Technologies LLC owned about 0.14% of Merus N.V. at the end of the most recent reporting period. Hedge funds and other institutional investors own 32.16% of the company’s stock.

Merus N.V. Company Profile

Receive News & Ratings for Merus N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus N.V. and related companies with's FREE daily email newsletter.

Leave a Reply